Russell Investments Group Ltd. Purchases 25,702 Shares of Repligen Corporation $RGEN

Key Points

• Russell Investments Group Ltd. increased its stake in Repligen Corporation by 44.2%, owning approximately $10.67 million worth of shares as of the latest SEC filing.
• Repligen reported a 14.8% year-over-year revenue increase for the last quarter, reaching $182.37 million, although its earnings per share missed expectations at $0.37.
• Institutional investors hold 97.64% of Repligen's stock, with several major funds increasing their positions, highlighting significant market interest in the company.

Russell Investments Group Ltd. grew its position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 44.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 83,874 shares of the biotechnology company's stock after purchasing an additional 25,702 shares during the quarter. Russell Investments Group Ltd. owned about 0.15% of Repligen worth $10,672,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Raiffeisen Bank International AG bought a new stake in shares of Repligen in the 4th quarter valued at $29,000. Itau Unibanco Holding S.A. bought a new stake in shares of Repligen in the 4th quarter valued at $40,000. Signaturefd LLC increased its stake in shares of Repligen by 65.3% in the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 128 shares in the last quarter. Center for Financial Planning Inc. increased its stake in shares of Repligen by 110.3% in the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock valued at $47,000 after acquiring an additional 193 shares in the last quarter. Finally, UMB Bank n.a. increased its stake in shares of Repligen by 99.4% in the 1st quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company's stock valued at $85,000 after acquiring an additional 332 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Insider Activity at Repligen

In other Repligen news, Director Martin D. Madaus bought 1,800 shares of the stock in a transaction dated Friday, August 8th. The shares were bought at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the purchase, the director directly owned 1,800 shares of the company's stock, valued at approximately $201,834. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on RGEN shares. Wall Street Zen lowered shares of Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Wells Fargo & Company reduced their price target on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research report on Wednesday, July 30th. Barclays started coverage on shares of Repligen in a research report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 price target for the company. Stephens raised shares of Repligen to an "overweight" rating and set a $160.00 price target for the company in a research report on Tuesday, July 22nd. Finally, JPMorgan Chase & Co. reduced their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $169.45.

Repligen Stock Down 1.6%

RGEN traded down $1.91 during mid-day trading on Thursday, reaching $119.65. 543,735 shares of the stock were exchanged, compared to its average volume of 929,898. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. The stock has a market capitalization of $6.73 billion, a PE ratio of -478.58, a price-to-earnings-growth ratio of 2.24 and a beta of 1.05. The company has a 50 day moving average price of $121.72 and a two-hundred day moving average price of $131.78. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The business had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company's revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, research analysts anticipate that Repligen Corporation will post 1.72 EPS for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.